國家衛生研究院 NHRI:Item 3990099045/1232

NHRI > Institute of Biotechnology and Pharmaceutical Research > Xin Chen(2002-2015) > Periodical Articles > Item 3990099045/1232

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/1232

Title:	Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
Authors:	Brandt, I;Joossens, J;Chen, X;Maes, MB;Scharpe, S;De Meester, I;Lambeir, AM
Contributors:	Division of Biotechnology and Pharmaceutical Research
Abstract:	Vildagliptin (NVP-LAF237/(2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl)}-pyrrolidine-2-carbonitrile) was described as a potent, selective and orally bio-available dipeptidyl-peptidase IV (DPP IV, EC 3.4.14.5) inhibitor [Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, et al. 1-[[(3-Hydroxy-1-adamantyl)amino] acetyl] - 2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89]. Phase III clinical trials for the use of this compound in the treatment of Type 2 diabetes were started in the first quarter of 2004. In this paper, we report on (1) the kinetics of binding, (2) the type of inhibition, (3) the selectivity with respect to other peptidases, and (4) the inhibitory potency on the DPP IV catalyzed degradation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and substance P. Vildagliptin behaved as a slow-binding DPP IV inhibitor with an association rate constant of 1.4 x 10(5) M-1 s(-1) and a K-i of 17 nM. It is a micromolar inhibitor for dipeptidyl-peptidase 8 and does not significantly inhibit dipeptidyl-peptidase II (EC 3.4.11.2), prolyl oligopeptidase (EC 3.4.21.26), aminopeptidase P (EC 3.4.11.9) or aminopeptidase M (EC 3.4.11.2). There was no evidence for substrate specific inhibition of DPP IV by Vildagliptin or for important allosteric factors affecting the inhibition constant in presence of GIP and GLP-1. (c) 2005 Elsevier Inc. All rights reserved.
Keywords:	Pharmacology & Pharmacy
Date:	2005-07-01
Relation:	Biochemical Pharmacology. 2005 Jul;70(1):134-143.
Link to:	http://dx.doi.org/10.1016/j.bcp.2005.04.009
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0006-2952&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000229979500014
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=20444406121
Appears in Collections:	[Xin Chen(2002-2015)] Periodical Articles

Files in This Item:

File	Description	Size	Format
000229979500014.pdf		342Kb	Adobe PDF	590	View/Open

Loading...